Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NGNE Neurogene Inc
- Stocks
- Healthcare
- NASDAQ: NGNE
Price (delayed)
$21.67
Market cap
$309.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.35
Enterprise value
$249.66M
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed
Highlights
NGNE's EPS has soared by 95% YoY
NGNE's quick ratio is up by 45% YoY
NGNE's equity has soared by 71% YoY but it is down by 6% QoQ
Neurogene's net income has shrunk by 97% YoY and by 8% QoQ
Key stats
What are the main financial stats of NGNE
Market
Valuations
Earnings
Shares outstanding
14.26M
Market cap
$309.06M
Enterprise value
$249.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$90.67M
Net income
-$80.87M
EBIT
-$80.86M
EBITDA
-$76.91M
Free cash flow
-$71.25M
Per share
Balance sheet
Liquidity
EPS
-$4.35
EPS diluted
-$4.35
Free cash flow per share
-$3.39
Book value per share
$19.54
Revenue per share
$0
TBVPS
$15.02
Total assets
$315.3M
Total liabilities
$23.51M
Debt
$11.71M
Equity
$291.8M
Working capital
$282.3M
Debt to equity
0.04
Current ratio
21.03
Quick ratio
20.78
Net debt/EBITDA
0.77
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.5%
Return on equity
-36.2%
Return on invested capital
-53.8%
Return on capital employed
-26.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NGNE stock price
How has the Neurogene stock price performed over time
Intraday
5.4%
1 week
22.71%
1 month
27.7%
1 year
-42.57%
YTD
-5.21%
QTD
85.06%
Financial performance
How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$90.67M
Net income
-$80.87M
Gross margin
N/A
Net margin
N/A
Neurogene's net income has shrunk by 97% YoY and by 8% QoQ
NGNE's operating income is down by 48% year-on-year and by 9% since the previous quarter
Price vs fundamentals
How does NGNE's price correlate with its fundamentals
Growth
What is Neurogene's growth rate over time
Valuation
What is Neurogene stock price valuation
P/E
N/A
P/B
1.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 95% YoY
NGNE's equity has soared by 71% YoY but it is down by 6% QoQ
The stock's price to book (P/B) is 50% less than its last 4 quarters average of 2.2 and 38% less than its 5-year quarterly average of 1.8
Efficiency
How efficient is Neurogene business performance
The company's return on invested capital rose by 27% QoQ and by 17% YoY
NGNE's return on assets is down by 19% year-on-year but it is up by 6% since the previous quarter
The ROE has contracted by 13% YoY but it has grown by 7% from the previous quarter
Dividends
What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NGNE.
Financial health
How did Neurogene financials performed over time
The total assets has soared by 61% YoY but it has contracted by 6% from the previous quarter
NGNE's quick ratio is up by 45% YoY
NGNE's debt is 96% smaller than its equity
NGNE's equity has soared by 71% YoY but it is down by 6% QoQ
Neurogene's debt to equity has plunged by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.